Artikel dengan mandat akses publik - David TernantPelajari lebih lanjut
Tidak tersedia di mana pun: 9
Non-linear rituximab pharmacokinetics and complex relationship between rituximab concentrations and anti-neutrophil cytoplasmic antibodies (ANCA) in ANCA-associated vasculitis …
A Bensalem, D Mulleman, G Paintaud, N Azzopardi, V Gouilleux-Gruart, ...
Clinical Pharmacokinetics 59 (4), 519-530, 2020
Mandat: US National Institutes of Health, Agence Nationale de la Recherche
The influence of underlying disease on rituximab pharmacokinetics may be explained by target-mediated drug disposition
A Bensalem, G Cartron, U Specks, D Mulleman, E Gyan, D Cornec, ...
Clinical Pharmacokinetics 61 (3), 423-437, 2022
Mandat: US National Institutes of Health, Agence Nationale de la Recherche
Infliximab treatment does not lead to full TNF-α inhibition: A target-mediated drug disposition model
D Ternant, M Pfister, O Le Tilly, D Mulleman, L Picon, S Willot, C Passot, ...
Clinical Pharmacokinetics, 1-12, 2022
Mandat: Agence Nationale de la Recherche
Population pharmacokinetics and exposure–response relationship of trastuzumab and bevacizumab in early-stage breast cancer
A Petitcollin, N Azzopardi, JY Pierga, D Ternant, I Navarro-Teulon, ...
European Journal of Clinical Pharmacology 77, 1861-1873, 2021
Mandat: Agence Nationale de la Recherche
Relationship between antithymocyte globulin concentrations and lymphocyte sub-populations in kidney transplant patients
N Azzopardi, H Longuet, D Ternant, G Thibault, V Gouilleux-Gruart, ...
Clinical Pharmacokinetics, 1-12, 2022
Mandat: Agence Nationale de la Recherche
Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction in Patients With Chronic Immune-Mediated Inflammatory Diseases
O Le Tilly, G Paintaud, D Ternant
JAMA 326 (11), 1069-1069, 2021
Mandat: US National Institutes of Health
Confounding mitigation for the exposure‐response relationship of bevacizumab in colorectal cancer patients
S Lobet, M Caulet, G Paintaud, N Azzopardi, C Desvignes, R Chautard, ...
British Journal of Clinical Pharmacology 90 (4), 976-986, 2024
Mandat: Agence Nationale de la Recherche
Relationship between cetuximab target-mediated pharmacokinetics and progression-free survival in metastatic colorectal cancer patients
S Lobet, G Paintaud, N Azzopardi, C Passot, M Caulet, R Chautard, ...
Clinical Pharmacokinetics 62 (9), 1263-1274, 2023
Mandat: Agence Nationale de la Recherche
Angiogenic factors could help us to define patients obtaining complete response with undetectable minimal residual disease in untreated CLL patients treated by FCR: results …
AL Gagez, F Paul, E Alaterre, V Gouilleux-Gruart, E Tuaillon, S Lepretre, ...
Leukemia & lymphoma 62 (13), 3160-3169, 2021
Mandat: Agence Nationale de la Recherche
Tersedia di suatu tempat: 21
Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial
E Ducourau, T Rispens, M Samain, E Dernis, F Le Guilchard, L Andras, ...
RMD open 6 (1), e001047, 2020
Mandat: Agence Nationale de la Recherche
Influence of antigen mass on the pharmacokinetics of therapeutic antibodies in humans
D Ternant, N Azzopardi, W Raoul, T Bejan-Angoulvant, G Paintaud
Clinical pharmacokinetics 58 (2), 169-187, 2019
Mandat: Agence Nationale de la Recherche
Model‐based design of rituximab dosage optimization in follicular non‐Hodgkin's lymphoma
D Ternant, G Cartron, E Hénin, M Tod, P Girard, G Paintaud
British journal of clinical pharmacology 73 (4), 597-605, 2012
Mandat: National Institute of Health and Medical Research, France
Development of a drug–disease simulation model for rituximab in follicular non‐Hodgkin's lymphoma
D Ternant, E Hénin, G Cartron, M Tod, G Paintaud, P Girard
British journal of clinical pharmacology 68 (4), 561-573, 2009
Mandat: National Institute of Health and Medical Research, France
A recycling anti-transferrin receptor-1 monoclonal antibody as an efficient therapy for erythroleukemia through target up-regulation and antibody-dependent cytotoxic effector …
M Neiveyans, R Melhem, C Arnoult, T Bourquard, M Jarlier, M Busson, ...
MAbs 11 (3), 593-605, 2019
Mandat: Agence Nationale de la Recherche
17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia
C Bagacean, A Tempescul, D Ternant, A Banet, N Douet-Guilbert, ...
Journal for ImmunoTherapy of Cancer 7, 1-5, 2019
Mandat: Swiss Cancer League
Enhanced amikacin diffusion with ultrasound and microbubbles in a mechanically ventilated condensed lung rabbit model
F Espitalier, F Darrouzain, JM Escoffre, D Ternant, E Piver, A Bouakaz, ...
Frontiers in pharmacology 10, 1562, 2020
Mandat: National Institute of Health and Medical Research, France
Feasibility and safety of tailored dosing schedule for eculizumab based on therapeutic drug monitoring: lessons from a prospective multicentric study
C Passot, R Sberro‐Soussan, D Bertrand, S Caillard, B Schvartz, ...
British journal of clinical pharmacology 87 (5), 2236-2246, 2021
Mandat: Agence Nationale de la Recherche
CD4+ count‐dependent concentration–effect relationship of rituximab in rheumatoid arthritis
A Bensalem, D Mulleman, G Thibault, N Azzopardi, P Goupille, ...
British Journal of Clinical Pharmacology 85 (12), 2747-2758, 2019
Mandat: Agence Nationale de la Recherche
Curcumin and NCLX inhibitors share anti-tumoral mechanisms in microsatellite-instability-driven colorectal cancer
M Guéguinou, S Ibrahim, J Bourgeais, A Robert, T Pathak, X Zhang, ...
Cellular and Molecular Life Sciences 79 (6), 284, 2022
Mandat: National Institute of Health and Medical Research, France, Swiss Cancer League
Therapeutic antibodies for the treatment of respiratory tract infections—Current overview and perspectives
A Mayor, A Chesnay, G Desoubeaux, D Ternant, N Heuzé-Vourc’h, ...
Vaccines 9 (2), 151, 2021
Mandat: Agence Nationale de la Recherche
Informasi terbitan dan pendanaan ditentukan secara otomatis oleh program komputer